May. 12 at 12:02 PM
$CTMX Most standard second-line regimens for mCRC achieve only about 10–20% ORR in unselected MSS patients. This is why companies developing new therapies for second-line MSS CRC often benchmark against historical Avastin + FOLFIRI data, where ORRs are just 6–15%.
This low bar is precisely what makes newer approaches, such as ADCs, immunotherapy combinations, so potentially impactful. If these therapies can generate ORRs in the range of 25–40%, they would be considered highly meaningful in MSS CRC.
CX2051+Avastin+std chemo has a strong chance of making meaningful difference in these patient populations
